The Case for a Bayesian Approach to Benefit-Risk Assessment:: Overview and Future Directions

Therapeutic Innovation & Regulatory Science
Maria J CostaCarl Di Casoli

Abstract

The benefit-risk assessment of a new medicinal product or intervention is one of the most complex tasks that sponsors, regulators, payers, physicians, and patients face. Therefore, communicating the trade-off of benefits and risks in a clear and transparent manner, using all available evidence, is critical to ensure that the best decisions are made. Several quantitative methods have been proposed in recent years that try to provide insight into this challenging problem. Bayesian inference, with its coherent approach for integrating different sources of information and uncertainty, along with its links to optimal decision theory, provides a natural framework to perform quantitative assessments of the benefit-risk trade-off. This paper describes the current state of the art in Bayesian methodologies for quantitative benefit-risk assessment, and how these may be leveraged throughout the life cycle of a medicinal product to support and augment clinical judgment and qualitative benefit-risk assessments. Gaps and potential new directions that extend the current approaches are also identified.

References

Nov 18, 1995·BMJ : British Medical Journal·P P Glasziou, L M Irwig
Mar 1, 1997·Clinical Pharmacology and Therapeutics·L B Sheiner
Dec 13, 2000·Statistics in Medicine·D Ashby, A F Smith
Aug 27, 2002·Journal of Pharmacokinetics and Pharmacodynamics·Gordon GrahamLeon Aarons
Sep 2, 2004·Biometrics·Peter F Thall, John D Cook
Jan 15, 2005·Journal of Clinical Epidemiology·Alexander J SuttonDavid R Jones
Oct 14, 2006·BMC Medical Research Methodology·Michele L Shaffer, Kristi L Watterberg
Sep 13, 2008·Nature Reviews. Drug Discovery·Hans-Georg EichlerAlasdair Breckenridge
Sep 1, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Ola CasterI Ralph Edwards
May 14, 2014·Pharmacoepidemiology and Drug Safety·Shahrul Mt-IsaUNKNOWN IMI-PROTECT benefit-risk participants
Jan 30, 2015·Biometrical Journal. Biometrische Zeitschrift·Ed WaddinghamDeborah Ashby
Apr 14, 2016·CPT: Pharmacometrics & Systems Pharmacology·UNKNOWN EFPIA MID3 WorkgroupS A G Visser
May 1, 2015·Therapeutic Innovation & Regulatory Science·Michael W ColopyZhong Yuan
Sep 1, 2014·Therapeutic Innovation & Regulatory Science·Bennett LevitanStuart Walker

❮ Previous
Next ❯

Citations

Apr 17, 2019·Statistics in Medicine·Kan LiShahrul Mt-Isa
Feb 24, 2018·Pharmaceutical Statistics·Maria J Costa, Thomas Drury

❮ Previous
Next ❯

Software Mentioned

MCDA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.